<DOC>
	<DOCNO>NCT02188160</DOCNO>
	<brief_summary>The primary purpose study determine efficacy safety KPI-121 0.25 % ophthalmic suspension compare vehicle ( placebo ) subject documented clinical diagnosis dry eye disease . The product study 28 day , 1-2 drop instill eye four time daily ( QID ) .</brief_summary>
	<brief_title>Safety Efficacy KPI-121 Subjects With Dry Eye Disease</brief_title>
	<detailed_description>This Phase II , multi-center , double-masked , randomize , vehicle-controlled , parallel-group study design evaluate safety efficacy KPI-121 0.25 % ophthalmic suspension versus vehicle subject dry eye disease . Approximately 400 subject screen 150 subject randomize 12 center locate United States . Subjects randomize 1 2 study arm approximate 1:1 ratio . The study arm : 1 ) KPI-121 0.25 % ophthalmic suspension administer 1-2 drop eye QID 28 day 2 ) vehicle administer 1-2 drop eye QID 28 day . This study include 6 clinic visit 6 week . At Visit 1 Screening ( 14 ± 1 day prior Day 1 ) , subject meet screen inclusion/exclusion criterion begin 2-week run-in period treat 1-2 drop single-masked vehicle eye QID 14 ± 1 day . At Visit 2 , Randomization ( Day 1 ) , subject continue meet inclusion/exclusion criterion eligible randomization 1 2 arm study ( i.e. , KPI-121 0.25 % ophthalmic suspension vehicle ) . Following randomization , subject instruct return clinic complete study evaluation Study Visits 4 6 ( Days 15 ± 1 day 29 ± 1 day , respectively ) . Subjects instructed return clinic diary collection in-clinic symptom assessment Visits 3 5 ( Days 8 ± 1 day 22 ± 1 day , respectively ) . The last dose investigational product final study visit occur upon completion 28 ± 1 day exposure investigational product . Subjects release study end Visit 6 ( Day 29 ± 1 day ) .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>• Have document clinical diagnosis dry eye disease eye Known hypersensitivity/contraindication study product ( ) component . History glaucoma , IOP &gt; 21 mmHg screen randomization visit , treat glaucoma either eye . Diagnosis : ongoing ocular infection ; severe/serious ocular condition judgment Investigator could confound study assessment limit compliance ; severe/serious systemic disease uncontrolled medical condition judgment Investigator could confound study assessment limit compliance ; expose investigational drug within 30 day prior screen . In opinion Investigator study coordinator , unwilling unable comply study protocol unable successfully instill eye drop .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Dry Eye</keyword>
	<keyword>Hyperemia</keyword>
	<keyword>Ocular Discomfort</keyword>
</DOC>